The Bristol-Myers Company presents an annual award to a scientist making an outstanding contribution in cancer research. The candidates for the award are to be nominated by medical schools, free-standing hospitals and cancer research centers. Only one nomination from each institution is permitted.

AWARD: $50,000 U.S.

DEADLINE FOR RECEIPT OF NOMINATIONS
December 15, 1982

ANNOUNCEMENT OF AWARD RECIPIENT
Spring 1983

SELECTION COMMITTEE
Saul A. Rosenberg, M.D., Selection Committee Chairman
Professor of Medicine and Radiology and Chief, Division of Oncology
Stanford University School of Medicine

Gianni Bonadonna, M.D.
Director, Division of Clinical Oncology
Istituto Nazionale per lo Studio e la Cura dei Tumori

Harris Busch, M.D., Ph.D.
Professor and Chairman
Department of Pharmacology
Baylor College of Medicine

Emil Frei, III, M.D.
Professor of Medicine, Harvard Medical School
Director and Physician-in-Chief
Sidney Farber Cancer Institute

Ken R. Harrap, Ph.D., D.Sc.
Head, Department of Biochemical Pharmacology
Institute of Cancer Research
Royal Marsden Hospital

Paul A. Marks, M.D.
President and Chief Executive Officer
Memorial Sloan-Kettering Cancer Center

Albert H. Owens, Jr., M.D.
Director, Oncology Center
The Johns Hopkins University
School of Medicine

Henry C. Piot, M.D., Ph.D.
Professor of Oncology and Pathology
University of Wisconsin Medical School
Director, McArdle Laboratory for Cancer Research

Alan C. Sartorelli, Ph.D.
Professor and Chairman
Department of Pharmacology
Yale University School of Medicine

Philip S. Schein, M.D.
Professor of Medicine and Pharmacology
and Chief, Division of Medical Oncology
Georgetown University School of Medicine

John E. Ultmann, M.D.
Director, Cancer Research Center
The University of Chicago

Rules and official nomination forms are available from: Secretary, Award Committee, 345 Park Avenue, Room 43-38, New York, New York 10154, or (212) 546-4339.
This month Cancer Research directs attention to developmental approaches to neoplasia, in particular research on teratocarcinomas. It was upon these tumors that differentiation of malignant stem cells into benign cells was first demonstrated in 1959 by G. B. Pierce and F. J. Dixon.

The research was made possible after L. C. Stevens and C. C. Little in 1954 established transplantable lines of teratocarcinomas in strain 129 mice. Stevens continued studies on the genetics of the tumors, their development, and experimental production. He discovered that spontaneous teratocarcinomas developed from primordial germ cells in the male and by parthenogenesis in the female. Tumors could be induced by transplanting eggs and embryos into the testis, arising from disorganized embryonic epithelium.

Pierce and his associates demonstrated the multipotent stem cell nature of embryonal carcinoma and the benign nature of the differentiated tissues derived from embryonal carcinoma, developed methods of mass producing embryoid bodies, and studied their development in vivo and in vitro.

The developmental implications of differentiation in neoplasms took a great leap forward in 1974, when R. L. Brinster, using techniques first developed by Richard Gardner, injected single embryonal carcinoma cells into the blastocyes of homologous mice and transferred the injected blastocyes into the uteri of pseudopregnant mice. Chimeric mice occurred in the resultant litters, as evidenced by coat color mosaicism. Cancer cells were thus regulated to behave like normal embryonic cells, which took part in the normal development of the skin. These results were confirmed and extended in two laboratories: B. Mintz et al., using isoenzyme markers demonstrated the proportion of cells in various organs that were derived from the cancer cell; and V. E. Papaioannou and her associates showed that there was a limit to the number of cancer cells that the blastocyte could control. It was then shown that there may be specificity to the reaction, in that the blastocyte could control only closely related malignant cell types.

If one embryonic environment can control its closely related carcinoma, there may be a controlling embryonic environment for each carcinoma. Study of these controls may lead to noncytotoxic therapy of cancer through directing the differentiation of malignant to benign cells.


Pictured are L. C. Stevens, of The Jackson Laboratory, Bar Harbor, Maine (left); G. Barry Pierce, of the Department of Pathology, University of Colorado, Denver (center); and Ralph L. Brinster, University of Pennsylvania, School of Veterinary Medicine (right). The section is of a teratocarcinoma of strain 129 mice, indicating some of its malignant and benign elements.

We are indebted to Dr. Pierce for the information and illustrations.

M.B.S.